2023
Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial
Greene S, Velazquez E, Anstrom K, Clare R, DeWald T, Psotka M, Ambrosy A, Stevens G, Rommel J, Alexy T, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Eisenstein E, Mentz R, Investigators O. Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. Circulation 2023, 148: 124-134. PMID: 37212600, PMCID: PMC10524905, DOI: 10.1161/circulationaha.123.064842.Peer-Reviewed Original ResearchConceptsPatient Health Questionnaire-2Prespecified secondary end pointsQuality of lifeEffects of torsemideSecondary end pointsHeart failurePatient-reported outcomesKansas City Cardiomyopathy Questionnaire clinical summary scoreNew York Heart Association classPatient Health Questionnaire-2 scoreEnd pointQuestionnaire-2Loop diuretic agentsLoop diuretic useProportion of patientsBaseline health statusClinical summary scoreEjection fraction phenotypeSignificant differencesDiuretic strategyTorsemide groupCause hospitalizationCause mortalityDiuretic usePrimary therapy
2020
Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial
Berk J, Damy T, Drachman B, Elliott P, Gottlieb S, Grogan M, Gundapaneni B, Hanna M, Hoffman J, Hummel S, Judge D, Lenihan D, Merlini G, Patterson T, Rapezzi C, Schwartz J, Shah S, Sultan M, Velazquez E, Cruz M, Witteles R. Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial. Heart & Lung 2020, 49: 209-210. DOI: 10.1016/j.hrtlng.2020.02.009.Peer-Reviewed Original ResearchEfficacy of tafamidisSix-minute walk distanceATTR-CMCause mortalityQuality of lifeWalk distanceHeart failureKansas City Cardiomyopathy Questionnaire overall scorePre-specified sensitivity analysisSix-minute walk test distanceTransthyretin Cardiomyopathy Clinical TrialHard cardiovascular endpointsFirst-line therapyKey secondary endpointPrimary efficacy analysisTransthyretin amyloid cardiomyopathyOverall scoreMechanical assist devicesClinical laboratory testsNovel study designNYHA classTafamidis groupPlacebo groupSecondary endpointsAdverse events
2018
HFrEF other treatment: revascularization
Velazquez E, Petrie M. HFrEF other treatment: revascularization. 2018, 1881-1884. DOI: 10.1093/med/9780198784906.003.0431.Peer-Reviewed Original Research
2017
Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial
DeVore AD, McNulty S, Alenezi F, Ersboll M, Vader JM, Oh JK, Lin G, Redfield MM, Lewis G, Semigran MJ, Anstrom KJ, Hernandez AF, Velazquez EJ. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. European Journal Of Heart Failure 2017, 19: 893-900. PMID: 28194841, PMCID: PMC5511088, DOI: 10.1002/ejhf.754.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkersDouble-Blind MethodEchocardiographyExercise ToleranceFemaleFollow-Up StudiesHeart Failure, SystolicHeart VentriclesHumansMaleMiddle AgedMyocardial ContractionNatriuretic Peptide, BrainOxygen ConsumptionPeptide FragmentsProcollagenQuality of LifeRetrospective StudiesStroke VolumeTime FactorsVentricular Function, LeftConceptsLV global longitudinal strainGlobal longitudinal strainImpaired LV global longitudinal strainVentricular global longitudinal strainEjection fractionQuality of lifeRELAX trialExercise capacityHeart failureN-terminal pro-brain natriuretic peptideLeft ventricular global longitudinal strainWorse LV global longitudinal strainLog-transformed NT-proBNPPro-brain natriuretic peptideNormal LV ejection fractionLongitudinal strainHeart failure scoreLV ejection fractionPeak oxygen consumptionHFpEF patientsMinnesota LivingDiastolic dysfunctionNT-proBNPSystolic dysfunctionClinical characteristics
2015
Use of outcome measures in pulmonary hypertension clinical trials
Parikh KS, Rajagopal S, Arges K, Ahmad T, Sivak J, Kaul P, Shah SH, Tapson V, Velazquez EJ, Douglas PS, Samad Z. Use of outcome measures in pulmonary hypertension clinical trials. American Heart Journal 2015, 170: 419-429.e3. PMID: 26385024, DOI: 10.1016/j.ahj.2015.06.010.Peer-Reviewed Original ResearchConceptsHypertension clinical trialsPulmonary arterial hypertensionPAH trialsClinical practiceInvasive hemodynamicsPrimary endpointClinical trialsOutcome measuresInvasive measuresSurrogate measureDuke University Medical CenterPatient-centered endpointsSecondary outcome measuresClinical treatment trialsMEDLINE/EMBASEUniversity Medical CenterSmall patient populationQuality of lifeContemporary clinical practicePAH therapyPH medicationsArterial hypertensionSerial echocardiographyPatient characteristicsSecondary outcomesRevascularization in Severe Left Ventricular Dysfunction
Velazquez EJ, Bonow RO. Revascularization in Severe Left Ventricular Dysfunction. Journal Of The American College Of Cardiology 2015, 65: 615-624. PMID: 25677320, DOI: 10.1016/j.jacc.2014.10.070.Peer-Reviewed Original ResearchConceptsLeft ventricular systolic dysfunctionVentricular systolic dysfunctionShort-term riskSurgical revascularizationSystolic dysfunctionSevere left ventricular systolic dysfunctionCoronary artery bypass graft surgeryArtery bypass graft surgeryHigh-risk patient populationBypass graft surgeryReduced ejection fractionCornerstone of treatmentHigh-risk patientsMitral valve surgerySurgical ventricular reconstructionGreater short-term riskImplantable device therapyQuality of lifeMultivessel diseaseGraft surgeryValve surgerySurgery needDevice therapyEjection fractionHeart failure
2014
Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction A VALIANT Study (Valsartan In Acute Myocardial Infarction)
Lewis EF, Li Y, Pfeffer MA, Solomon SD, Weinfurt KP, Velazquez EJ, Califf RM, Rouleau JL, Kober L, White HD, Schulman KA, Reed SD. Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction A VALIANT Study (Valsartan In Acute Myocardial Infarction). JACC Heart Failure 2014, 2: 159-165. PMID: 24720924, DOI: 10.1016/j.jchf.2013.12.003.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsBundle-Branch BlockCaptoprilDeath, Sudden, CardiacDrug Therapy, CombinationFemaleHealth StatusHeart FailureHospitalizationHumansMaleMyocardial InfarctionQuality of LifeRecurrenceStrokeSurvivorsTetrazolesTreatment OutcomeValineValsartanConceptsNonfatal CV eventsEQ-5D assessmentCV eventsVisual analog scaleEQ-5D scoresCardiovascular eventsMyocardial infarctionEQ-5DBaseline EQ-5D scoresKillip class IINonfatal cardiovascular eventsHealth-related qualityLinear mixed-effects regression modelsQuality of lifeMixed effects regression modelsVALIANT studyWorse HRQLVAS scoresEjection fractionNonfatal eventsMI survivorsAnalog scaleVALIANT trialGeneric instrumentsPatientsPROspective Multicenter Imaging Study for Evaluation of chest pain: Rationale and design of the PROMISE trial
Douglas PS, Hoffmann U, Lee KL, Mark DB, Al-Khalidi HR, Anstrom K, Dolor RJ, Kosinski A, Krucoff MW, Mudrick DW, Patel MR, Picard MH, Udelson JE, Velazquez EJ, Cooper L, investigators P. PROspective Multicenter Imaging Study for Evaluation of chest pain: Rationale and design of the PROMISE trial. American Heart Journal 2014, 167: 796-803.e1. PMID: 24890527, PMCID: PMC4044617, DOI: 10.1016/j.ahj.2014.03.003.Peer-Reviewed Original ResearchConceptsCoronary artery diseasePROMISE trialAnatomical testingProspective Multicenter Imaging StudyDiagnostic strategiesInitial diagnostic strategyMajor procedural complicationsSubsequent care decisionsComposite of deathPrimary end pointLarge pragmatic trialClinical care teamQuality of lifeDiagnostic testing strategiesMultidetector coronaryChest painSymptomatic patientsUnstable anginaArtery diseaseProcedural complicationsRandomized trialsSymptomatic subjectsClinical effectivenessMyocardial infarctionPragmatic trial
2009
Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: Results from the Surgical Treatment for Ischemic Heart Failure trial
Mark DB, Knight JD, Velazquez EJ, Howlett JG, Spertus JA, Djokovic LT, Harding TM, Rankin GR, Drew LA, Szygula-Jurkiewicz B, Adlbrecht C, Anstrom KJ, Investigators F. Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: Results from the Surgical Treatment for Ischemic Heart Failure trial. American Heart Journal 2009, 157: 837-844.e3. PMID: 19376309, PMCID: PMC2694042, DOI: 10.1016/j.ahj.2009.03.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedCoronary Artery BypassFemaleFollow-Up StudiesHealth Care CostsHeart FailureHeart VentriclesHumansMaleMiddle AgedMyocardial IschemiaPlastic Surgery ProceduresQuality of LifeRetrospective StudiesStroke VolumeSurveys and QuestionnairesTreatment OutcomeUnited StatesVentricular Function, LeftConceptsCoronary artery bypass graft surgerySurgical ventricular reconstructionIschemic heart failureQuality of lifeHeart failureVentricular reconstructionQOL measuresIschemic Heart Failure (STICH) trialKansas City Cardiomyopathy QuestionnaireTotal index hospitalization costsArtery bypass graft surgeryLeft ventricular ejection fractionBetter QOLIndex hospitalization costsBypass graft surgeryHeart failure symptomsHeart Failure TrialVentricular ejection fractionLeft ventricular functionHealth care costsTreatment-related differencesGraft surgeryEjection fractionSurgical treatmentVentricular function
2007
The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial
Velazquez EJ, Lee KL, O’Connor C, Oh JK, Bonow RO, Pohost GM, Feldman AM, Mark DB, Panza JA, Sopko G, Rouleau JL, Jones RH, Investigators S. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. Journal Of Thoracic And Cardiovascular Surgery 2007, 134: 1540-1547.e4. PMID: 18023680, PMCID: PMC3638867, DOI: 10.1016/j.jtcvs.2007.05.069.Peer-Reviewed Original ResearchConceptsIschemic Heart Failure (STICH) trialCoronary artery bypassHeart Failure TrialSurgical ventricular reconstructionArtery bypassMedical therapySurgical treatmentFailure TrialVentricular reconstructionPrimary outcomeNormal left ventricular sizeIntensive medical therapyLeft ventricular dysfunctionVentricular ejection fractionCoronary artery diseaseLeft ventricular sizeLong-term survivalQuality of lifeLeft ventricular volumeCardiac causesSubsequent hospitalizationVentricular dysfunctionArtery diseaseEjection fractionHeart failure
2005
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA, Investigators F. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). American Heart Journal 2005, 150: 323-329. PMID: 16086938, DOI: 10.1016/j.ahj.2004.08.037.Peer-Reviewed Original ResearchMeSH KeywordsAmbulatory CareAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCaptoprilDrug CostsGlobal HealthHealth Care CostsHealth ResourcesHeart FailureHospital CostsHospitalizationHumansMyocardial InfarctionProspective StudiesQuality of LifeTetrazolesValineValsartanVentricular Dysfunction, LeftConceptsQuality of lifeMyocardial infarctionAcute Myocardial Infarction trialLower medication costsMyocardial Infarction trialHealth-related qualityLinear mixed-effects regression analysisMultinational clinical trialsMixed-effects regression analysisCaptopril groupStudy medicationCardiovascular morbidityVentricular dysfunctionMost patientsHeart failureACE inhibitorsMedication costsProspective economic evaluationClinical trialsHigh riskPatientsValsartanResource useCaptoprilSignificant differences